Role of TSH receptor autoantibodies for the diagnosis of graves' disease and for the prediction of the course of hyperthyroidism and ophthalmopathy. recommendations of the thyroid section of the german society of endocrinology;Bedeutung der TSH-Rezeptor-Antikörper für die Diagnose des Morbus Basedow sowie die Prognoseabschätzung der Schilddrüsenü berfunktion und der endokrinen Orbitopathie : Stellungnahme der Sektion Schilddrüse der DGE

Medizinische Klinik

Volumn 104, Issue 5, 2009, Pages 343-348

  Eckstein, Anja ^a   Mann, Klaus ^a   Kahaly, George J ^b   Grußendorf, Martin ^c   Reiners, Christoph ^d   Feldkamp, Joachim ^e   Quadbeck, Beate ^f   Bockisch, Andreas ^a   Schott, Matthias ^g  

^a UNIVERSITY HOSPITAL ESSEN   (Germany)

^b UNIVERSITY MEDICAL CENTER MAINZ   (Germany)

^c Gemeinschaftspraxis Endokrinologie und Diabetologie   (Germany)

^d UNIVERSITY OF WÜRZBURG   (Germany)

^e OWL University   (Germany)

^f Abteilung für Endokrinologie   (Germany)

^g UNIVERSITY HOSPITAL DÜSSELDORF   (Germany)

Author keywords

Graves' disease; Graves' ophthalmopathy; TSH receptor antibodies

Indexed keywords

ANTITHYROID AGENT; RADIOACTIVE IODINE; THYROTROPIN RECEPTOR ANTIBODY; THYROTROPIN RECEPTOR AUTOANTIBODY; UNCLASSIFIED DRUG;

ANTIBODY TITER; AUTOIMMUNE DISEASE; BLOOD LEVEL; CONCENTRATION (PARAMETERS); DISEASE COURSE; ENDOCRINOLOGY; EYE DISEASE; FOLLOW UP; GRAVES DISEASE; HUMAN; HYPERTHYROIDISM; OUTCOME ASSESSMENT; PREDICTION; PROGNOSIS; REVIEW; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; TREATMENT INDICATION;

ANTITHYROID AGENTS; AUTOANTIBODIES; EVIDENCE-BASED MEDICINE; GRAVES DISEASE; GRAVES OPHTHALMOPATHY; HUMANS; HYPERTHYROIDISM; IODINE RADIOISOTOPES; PROGNOSIS; RECEPTORS, THYROTROPIN; THYROIDECTOMY;

EID: 66149102766     PISSN: 07235003     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00063-009-1072-0     Document Type: Review

References (58)

1. T. Ando R. Latif A. Pritsker 2002 A monoclonal thyroid-stimulating antibody J Clin Invest 110 1667 74 (Pubitemid 35424245)
2. V.A. Andrade J.L. Gross A.L. Maia 2004 Serum thyrotropin-receptor autoantibodies levels after I therapy in Graves' patients: effect of pretreatment with methimazole evaluated by a prospective, randomized study Eur J Endocrinol 151 467 74 (Pubitemid 39430265)
3. R.S. Bahn C.M. Dutton N. Natt 1998 Thyrotropin receptor expression in Graves' orbital adipose/connective tissues: potential autoantigen in Graves' ophthalmopathy J Clin Endocrinol Metab 83 998 1002 (Pubitemid 28496482)
4. L. Bartalena C. Marcocci L. Tanda 2002 Management of thyroid eye disease Eur J Nucl Med Mol Imaging 29 Suppl2 S458 65
5. L. Bartalena M.L. Tanda F. Bogazzi 2005 An update on the pharmacological management of hyperthyroidism due to Graves' disease Expert Opin Pharmacother 6 851 61 (Pubitemid 40946151)
6. G. Benker P. Kotulla P. Kendall-Taylor 1989 TSH binding-inhibiting antibodies in hyperthyroidism: relationship to clinical signs and hormone levels Clin Endocrinol (Oxf) 30 19 28 (Pubitemid 19052693)
7. G. Benker P. Vitti G. Kahaly 1995 Response to methimazole in Graves' disease. The European Multicenter Study Group Clin Endocrinol (Oxf) 43 257 63
8. C. Carella G. Mazziotti F. Sorvillo 2006 Serum thyrotropin receptor antibodies concentrations in patients with Graves' disease before, at the end of methimazole treatment, and after drug withdrawal: evidence that the activity of thyrotropin receptor antibody and/or thyroid response modify during the observation period Thyroid 16 295 302
9. S. Costagliola J.D. Franssen M. Bonomi 2002 Generation of a mouse monoclonal TSH receptor antibody with stimulating activity Biochem Biophys Res Commun 299 891 6 (Pubitemid 36034570)
10. S. Costagliola N.G. Morgenthaler R. Hoermann 1999 Second generation assay for thyrotropin receptor antibodies has superior diagnostic sensitivity for Graves' disease J Clin Endocrinol Metab 84 90 7 (Pubitemid 29036685)
11. M.S. Crisp C. Lane M. Halliwell 1997 Thyrotropin receptor transcripts in human adipose tissue J Clin Endocrinol Metab 82 2003 5 (Pubitemid 127495225)
12. S. Dunkelmann V. Neumann U. Staub 2005 Results of a risk adapted and functional radioiodine therapy in Graves' disease Nuklearmedizin 44 238 42 (Pubitemid 43027152)
13. A. Eckstein C. Loesch D. Glowacka 2009 Euthyroid and primarily hypothyroid patients develop milder and significantly more asymmetric Graves ophthalmopathy Br J Ophthalmol 67 607 12
14. A.K. Eckstein A. Finkenrath A. Heiligenhaus 2004 Dry eye syndrome in thyroid-associated ophthalmopathy: lacrimal expression of TSH receptor suggests involvement of TSHR-specific autoantibodies Acta Ophthalmol Scand 82 291 7 (Pubitemid 38714645)
15. A.K. Eckstein H. Lax C. Losch 2007 Patients with severe Graves' ophthalmopathy have a higher risk of relapsing hyperthyroidism and are unlikely to remain in remission Clin Endocrinol (Oxf) 67 607 12 (Pubitemid 47416321)
16. A.K. Eckstein M. Plicht H. Lax 2004 Clinical results of anti-inflammatory therapy in Graves' ophthalmopathy and association with thyroidal autoantibodies Clin Endocrinol (Oxf) 61 612 8 (Pubitemid 39540364)
17. A.K. Eckstein M. Plicht H. Lax 2006 Thyrotropin receptor autoantibodies are independent risk factors for Graves' ophthalmopathy and help to predict severity and outcome of the disease J Clin Endocrinol Metab 91 3464 70 (Pubitemid 44402120)
18. U. Feldt-Rasmussen H. Schleusener P. Carayon 1994 Meta-analysis evaluation of the impact of thyrotropin receptor antibodies on long term remission after medical therapy of Graves' disease J Clin Endocrinol Metab 78 98 102 (Pubitemid 24026755)
19. M.N. Gerding J.W. van der Meer M. Broenink 2000 Association of thyrotrophin receptor antibodies with the clinical features of Graves' ophthalmopathy Clin Endocrinol (Oxf) 52 267 71 (Pubitemid 30169681)
20. L. Giovanella L. Ceriani S. Garancini 2001 Clinical applications of the 2nd generation assay for anti-TSH receptor antibodies in Graves' disease. Evaluation in patients with negative 1st generation test Clin Chem Lab Med 39 25 8 (Pubitemid 32186275)
21. D. Glinoer P. de Nayer M. Bex 2001 Effects of 1-thyroxine administration, TSH-receptor antibodies and smoking on the risk of recurrence in Graves' hyperthyroidism treated with antithyroid drugs: a double-blind prospective randomized study Eur J Endocrinol 144 475 83 (Pubitemid 32487523)
22. J. Hensen P. Kotulla R. Finke 1984 10 years experience with consecutive measurement of thyrotropin binding inhibiting antibodies (TBIAb) J Endocrinol Invest 7 215 20 (Pubitemid 14089291)
23. D. Hermsen M. Broecker-Preuss M. Casati 2009 Technical evaluation of the first fully automated assay for the detection of TSH receptor autoantibodies Clin Chim Acta 401 84 9
24. R. Hoermann B. Quadbeck U. Roggenbuck 2002 Relapse of Graves' disease after successful outcome of antithyroid drug therapy: results of a prospective randomized study on the use of levothyroxine Thyroid 12 1119 28 (Pubitemid 36114820)
25. A. Kakinuma I. Morimoto T. Kuroda 1999 Comparison of recombinant human thyrotropin receptors versus porcine thyrotropin receptors in the thyrotropin binding inhibition assay for thyrotropin receptor autoantibodies Thyroid 9 849 55 (Pubitemid 29480751)
26. K. Kamijo 2003 TSH-receptor antibody measurement in patients with various thyrotoxicosis and Hashimoto's thyroiditis: a comparison of two two-step assays, coated plate ELISA using porcine TSH-receptor and coated tube radioassay using human recombinant TSH-receptor Endocr J 50 113 6 (Pubitemid 36305855)
27. D.H. Khoo S.C. Ho L.L. Seah 1999 The combination of absent thyroid peroxidase antibodies and high thyroid-stimulating immunoglobulin levels in Graves' disease identifies a group at markedly increased risk of ophthalmopathy Thyroid 9 1175 80 (Pubitemid 30038925)
28. P. Laurberg G. Wallin L. Tallstedt 2008 TSH-receptor autoimmunity in Graves' disease after therapy with anti-thyroid drugs, surgery, or radioiodine: a 5-year prospective randomized study Eur J Endocrinol 158 69 75
29. N. Manji J.D. Carr-Smith K. Boelaert 2006 Influences of age, gender, smoking, and family history on autoimmune thyroid disease phenotype J Clin Endocrinol Metab 91 4873 80
30. C. Massart J. Orgiazzi D. Maugendre 2001 Clinical validity of a new commercial method for detection of TSH-receptor binding antibodies in sera from patients with Graves' disease treated with antithyroid drugs Clin Chim Acta 304 39 47 (Pubitemid 32124737)
31. D. Maugendre C. Massart 2001 Clinical value of a new TSH binding inihibitory activity assay using human TSH receptors in the follow-up of antithyroid drug treated Graves' disease. Comparison with thyroid stimulating antibody bioassay Clin Endocrinol (Oxf) 54 89 96 (Pubitemid 32158710)
32. J. Meller I. Schreivogel A. Bergmann 2000 Clinical implications of a new TSH receptor antibody assay (DYNOtest TRAKhuman) in autoimmune thyroid diseases Nuklearmedizin 39 14 8 (Pubitemid 30163184)
33. Morgenthaler N. TSH-receptor autoantibodies. In: Wiersinga W, Drexhage HA, Weetman AP, et al., eds. The thyroid and autoimmunity. Stuttgart-New York: Thieme, 2006:126-32.
34. N.G. Morgenthaler S.C. Ho W.B. Minich 2007 Stimulating and blocking thyroid-stimulating hormone (TSH) receptor autoantibodies from patients with Graves' disease and autoimmune hypothyroidism have very similar concentration, TSH receptor affinity, and binding sites J Clin Endocrinol Metab 92 1058 65 (Pubitemid 46465683)
35. M.P. Mourits M.F. Prummel W.M. Wiersinga 1997 Clinical Activity Score as a guide in the management of patients with Graves' ophthalmopathy Clin Endocrinol (Oxf) 47 9 14 (Pubitemid 27313981)
36. J.Y. Noh N. Hamada Y. Inoue 2000 Thyroid-stimulating antibody is related to Graves' ophthalmopathy, but thyrotropin-binding inhibitor immunoglobulin is related to hyperthyroidism in patients with Graves' disease Thyroid 10 809 13
37. Y. Okamoto S. Tanigawa K. Ishikawa 2006 TSH receptor antibody measurements and prediction of remission in Graves' disease patients treated with minimum maintenance doses of antithyroid drugs Endocr J 53 467 72 (Pubitemid 44351496)
38. J. Orgiazzi A.M. Madec 2002 Reduction of the risk of relapse after withdrawal of medical therapy for Graves' disease Thyroid 12 849 53 (Pubitemid 35332988)
39. P. Perros P. Kendall-Taylor 1998 Natural history of thyroid eye disease Thyroid 8 423 5 (Pubitemid 28252426)
40. P. Perros P. Kendall-Taylor C. Neoh 2005 A prospective study of the effects of radioiodine therapy for hyperthyroidism in patients with minimally active Graves' ophthalmopathy J Clin Endocrinol Metab 90 5321 3 (Pubitemid 41262294)
41. B. Quadbeck R. Hoermann S. Hahn 2005 Binding, stimulating and blocking TSH receptor antibodies to the thyrotropin receptor as predictors of relapse of Graves' disease after withdrawal of antithyroid treatment Horm Metab Res 37 745 50 (Pubitemid 43028076)
42. B. Quadbeck U. Roggenbuck O.E. Janssen 2006 Impact of smoking on the course of Graves' disease after withdrawal of antithyroid drugs Exp Clin Endocrinol Diabetes 114 406 11 (Pubitemid 44620482)
43. M.J. Reinhardt I. Brink A.Y. Joe 2002 Radioiodine therapy in Graves' disease based on tissue-absorbed dose calculations: effect of pre-treatment thyroid volume on clinical outcome Eur J Nucl Med Mol Imaging 29 1118 24
44. O. Sabri M. Zimny M. Schreckenberger 2001 Characterization of therapy failures in radioiodine therapy of Graves' disease without simultaneous antithyroid agents Nuklearmedizin 40 1 6 (Pubitemid 32163550)
45. J. Sanders M. Evans L.D. Premawardhana 2003 Human monoclonal thyroid stimulating autoantibody Lancet 362 126 8 (Pubitemid 36831025)
46. M. Schott A.K. Eckstein H.S. Willenberg 2007 Improved prediction of relapse of Graves' thyrotoxicosis by combined determination of TSH receptor and thyroperoxidase antibodies Horm Metab Res 39 56 61 (Pubitemid 46535158)
47. M. Schott J. Feldkamp C. Bathan 2000 Detecting TSH-receptor antibodies with the recombinant TBII assay: technical and clinical evaluation Horm Metab Res 32 429 35
48. Schott M, Hermsen D, Broecker-Preuss M, et al. Clinical value of the first automated TSH receptor autoantibody assay for the diagnosis of Graves' disease: an international multicenter trial. Clin Endocrinol (Oxf) 2009:in press.
49. M. Schott N.G. Morgenthaler R. Fritzen 2004 Levels of autoantibodies against human TSH receptor predict relapse of hyperthyroidism in Graves' disease Horm Metab Res 36 92 6 (Pubitemid 38392248)
50. L. Tallstedt G. Lundell O. Torring 1992 Occurrence of ophthalmopathy after treatment for Graves' hyperthyroidism. The Thyroid Study Group N Engl J Med 326 1733 8
51. C.B. Terwee M.F. Prummel M.N. Gerding 2005 Measuring disease activity to predict therapeutic outcome in Graves' ophthalmopathy Clin Endocrinol (Oxf) 62 145 55 (Pubitemid 40203908)
52. I.M. Wakelkamp O. Bakker L. Baldeschi 2003 TSH-R expression and cytokine profile in orbital tissue of active vs. inactive Graves' ophthalmopathy patients Clin Endocrinol (Oxf) 58 280 7 (Pubitemid 36308115)
53. A.P. Weetman 2003 Graves' disease 1835-2002 Horm Res 59 Suppl1 114 8 (Pubitemid 36173419)
54. W.M. Wiersinga L. Bartalena 2002 Epidemiology and prevention of Graves' ophthalmopathy Thyroid 12 855 60 (Pubitemid 35332989)
55. T. Zimmermann-Belsing B. Nygaard A.K. Rasmussen 2002 Use of the 2nd generation TRAK human assay did not improve prediction of relapse after antithyroid medical therapy of Graves' disease Eur J Endocrinol 146 173 7 (Pubitemid 34162908)
56. K. Zöphel P. von Landenberg D. Roggenbuck 2008 Are porcine and human TSH receptor antibody measurements comparable? Clin Lab 54 1 8
57. K. Zöphel G. Wunderlich R. Koch 2000 Measurement of thyrotropin receptor antibodies (TRAK) with a second generation assay in patients with Graves' disease Nuklearmedizin 39 113 20 (Pubitemid 30489476)
58. K. Zöphel G. Wunderlich C. Kopprasch 2003 Predictive value of thyrotropin receptor antibodies using the second generation TRAb human assay after radioiodine treatment in Graves' disease Nuklearmedizin 42 63 70 (Pubitemid 36396047)